{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-048529","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.977065+00:00","generated_at":"2026-05-25T07:12:41.269704+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nuvation Bio: taletrectinib NDA Priority Review, $250M financing, Q4 net loss $49.4M","bullets":["FDA accepted NDA for taletrectinib with Priority Review; PDUFA goal date June 23, 2025 for advanced ROS1+ NSCLC.","Secured up to $250M non-dilutive financings from Sagard: $150M royalty interest plus $50M debt upon FDA approval.","Q4 net loss $49.4M ($0.15/sh) vs $13.8M ($0.06) in Q4 2023; R&D and SG&A rose due to AnHeart acquisition.","China NMPA approved taletrectinib Jan 2025 (Innovent commercializing); Nippon Kayaku submitted MAA in Japan.","Launched U.S. Expanded Access Program for taletrectinib in February 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-048529","json":"https://secwatch.observer/filing/0001193125-25-048529.json","markdown":"https://secwatch.observer/filing/0001193125-25-048529.md","text":"https://secwatch.observer/filing/0001193125-25-048529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525048529/0001193125-25-048529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525048529/d910737d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T07:12:41.269704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}